Lupus Nephritis (LN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Lupus nephritis (LN) is a severe complication in patients with systemic lupus erythematosus (SLE). Its prevalence varies depending on factors such as ethnicity, sex, and age of disease onset, ranging from 35% to 60%. LN, along with increased susceptibility to infections, significantly contributes to the morbidity and mortality of SLE patients. Histologically observed in most SLE patients (even those without apparent renal symptoms), renal involvement is characterized by hypertension, proteinuria, and eventual renal failure. Lupus nephritis is classified into six classes based on kidney biopsy findings: minimal mesangial lupus nephritis (class I), mesangial proliferative lupus nephritis (class II), focal lupus nephritis (class III), diffuse lupus nephritis (class IV), membranous lupus nephritis (class V), and advanced sclerosing lupus nephritis (class VI). The pathogenesis of LN is complex. It involves abnormalities in various immune system components, including B and T cells, the complement cascade, cytokines, and clearance of apoptotic cells. The diagnosis of LN is suspected based on changes in laboratory parameters, such as elevated creatinine levels, the presence of hematuria and proteinuria, and low serum complement levels. Treatment approaches for LN commonly involve a combination therapy of corticosteroids with either cyclophosphamide or mycophenolate. Once remission is achieved, maintenance therapy consists of gradually reducing the corticosteroid dosage and using an antimetabolite. The differential diagnosis for LN includes other causes of nephrotic syndrome, nephrolithiasis, hydronephrosis, medication-induced acute kidney injury, and acute interstitial nephritis. The long-term prognosis of LN varies depending on the class of nephritis. Classes I (minimal) and II (proliferative mesangial) generally have a favorable prognosis, while prognosis worsens as the disease progresses through different classes. Class III has a poor prognosis, and class IV is associated with the poorest prognosis. The timing of therapy initiation also affects prognosis, with earlier treatment initiation leading to better disease outcomes.
• The estimated annual prevalence of lupus nephritis in the USA is approximately 21.2 cases per 100,000 individuals.

Thelansis’s “Lupus Nephritis (LN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lupus Nephritis (LN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Lupus Nephritis (LN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Lupus Nephritis (LN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Lupus Nephritis (LN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Lupus Nephritis (LN), Lupus Nephritis (LN) market outlook, Lupus Nephritis (LN) competitive landscape, Lupus Nephritis (LN) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)